Organigram Q2 2026 Earnings: Revenue Falls, Profitability Pressured Despite Margin Stabilization

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

Organigram's Q2 fiscal 2026 net revenue falls 9% to $59.8 million, and adjusted EBITDA drops 82% to $0.9 million, as vapes, infused pre-rolls and higher returns weigh on margins. The company posts a $0.9 million net loss.

• Operators: Product mix and returns provisions drove the margin squeeze, even with record harvest volumes above 32,000 kg and better THC potency. Weak vape and infused pre-roll execution shows how quickly returns can erode recreational profitability.
• Investors: Cash burn improves, with free cash flow at -$7.0 million versus -$23.1 million a year earlier. Cash is $54.8 million, down 35%, and fiscal 2026 net revenue guidance now exceeds $350 million with the Sanity Group acquisition.
• Do now: Review your returns provisions and the product mix by category, especially vapes and infused pre-rolls, to see where returns are eating into margin.

Short on time? You’re done. Want the numbers?Keep reading ↓

Organigram Global reported weaker second-quarter fiscal 2026 results as revenue, margins, and adjusted EBITDA declined year-over-year, reflecting operational challenges in vapes and infused pre-rolls alongside slower industry growth.

The company generated net revenue of $59.8 million, down 9% year-over-year from $65.6 million. Gross revenue also fell 9% to $93.3 million.

Key Financial Metrics

Revenue

• Net revenue: $59.8 million (-9% YoY)
• Gross revenue: $93.3 million (-9% YoY)
• International revenue: $6.1 million (flat YoY)

Gross Profit & Margins

• Gross margin: 27%, down from 28%
• Adjusted gross margin: 31%, down from 33%
• Gross margin before fair value adjustments: 25%, down from 30%

The company said product mix deterioration and higher returns pressured profitability during the quarter.

Net Income / Net Loss

• Net loss: $0.9 million
• Prior-year quarter: $42.5 million net income

Results were negatively affected by:

• Lower revenue
• Weaker margins
• Reduced derivative valuation gains
• a $5.8 million impairment tied to the U.S. hemp-derived products business.

Adjusted EBITDA

• Adjusted EBITDA: $0.9 million
• Prior-year quarter: $4.9 million
• Decline: 82% YoY

Adjusted EBITDA deterioration reflected weaker recreational cannabis sales and increased returns provisions.

Operating Cash Flow & Free Cash Flow

• Operating cash flow: -$6.8 million
• Free cash flow: -$7.0 million

While still negative, cash burn improved materially from the prior-year period:

• Prior operating cash flow: -$16.6 million
• Prior free cash flow: -$23.1 million

Balance Sheet & Liquidity

• Cash and short-term investments: $54.8 million
• Total liabilities: $149.5 million
• Shareholders’ equity: $371.8 million

Cash declined 35% from fiscal year-end levels, partly due to the subsequent acquisition of Germany-based Sanity Group and related financing activities.

Operational Highlights

Organigram highlighted:

• record quarterly harvest volumes exceeding 32,000 kg
• improved THC potency
• Australian product launches
• continued, EU-GMP certification progress
• the acquisition of German cannabis company Sanity Group.

The company now expects fiscal 2026 net revenue to exceed $350 million following the Sanity acquisition.

Investor Takeaway

Despite maintaining market share leadership in several Canadian categories, Organigram’s quarter reflected meaningful profitability pressure:

• Declining revenue
• Weaker margins
• Sharply lower adjusted EBITDA
• Negative cash flow
• Impairment charges.

Management said operational stabilization efforts are underway and expects stronger execution in the second half of fiscal 2026, supported by international growth and the consolidation of Sanity Group.